Literature DB >> 2298157

Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone.

P B Grino1, J E Griffin, J D Wilson.   

Abstract

Testosterone and dihydrotestosterone are believed to exert their androgenic effects by interacting with a single intracellular receptor protein in androgen target tissues. During fetal life, however, testosterone mediates the virilization of the Wolffian ducts into the epididymis, vas deferens, and seminal vesicles, whereas the urogenital sinus and external genitalia require the in situ conversion of testosterone to dihydrotestosterone to undergo male development. The reason why the signal provided by testosterone needs to be amplified in some androgen target tissues but not in others remains an enigma. To provide insight into the different actions of these androgens we studied their interaction with the human androgen receptor in fibroblasts cultured from the genital skin of a patient with 5 alpha-reductase deficiency. Dihydrotestosterone was formed in negligible amounts in these cells, and in some experiments the residual 5 alpha-reductase activity was further blocked with the 5 alpha-reductase inhibitor finasteride. Saturation analysis in fibroblast monolayers disclosed similar amounts of binding with testosterone and dihydrotestosterone, and the affinity of binding of dihydrotestosterone was, on the average, about 2-fold greater than that of testosterone. [3H]Testosterone also exhibited a 5-fold faster dissociation rate from the receptor than [3H]dihydrotestosterone. In thermolability experiments the [3H]testosterone-receptor complex displayed marked instability at 42 C with 2 nM [3H] testosterone, whereas with 20 nM [3H]testosterone, receptor stability was similar to that seen with [3H]dihydrotestosterone. In up-regulation experiments, 2 nM [3H]testosterone produced a 34% increase in specific androgen receptor binding after 24 h, whereas 20 nM [3H]testosterone produced an average increase of 64%. Our results suggest that the weaker androgenic potency of testosterone compared to that of dihydrotestosterone resides in its weaker interaction with the androgen receptor, most clearly demonstrable as an increase in the dissociation rate of testosterone from the receptor. When present in relatively high concentrations, however, testosterone overcomes this defect by mass action.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2298157     DOI: 10.1210/endo-126-2-1165

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  82 in total

Review 1.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

2.  Finasteride for chronic central serous chorioretinopathy.

Authors:  Farzin Forooghian; Annal D Meleth; Catherine Cukras; Emily Y Chew; Wai T Wong; Catherine B Meyerle
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

3.  Androgen receptors in cultured rat adipose precursor cells during proliferation and differentiation: regional specificities and regulation by testosterone.

Authors:  M N Dieudonne; R Pecquery; M C Leneveu; A M Jaubert; Y Giudicelli
Journal:  Endocrine       Date:  1995-07       Impact factor: 3.633

4.  Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.

Authors:  S S Dadras; X Cai; I Abasolo; Z Wang
Journal:  Gene Expr       Date:  2001

Review 5.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

6.  Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Authors:  Elahe A Mostaghel; Peter S Nelson; Paul Lange; Daniel W Lin; Mary Ellen Taplin; Steven Balk; William Ellis; Philip Kantoff; Brett Marck; Daniel Tamae; Alvin M Matsumoto; Lawrence D True; Robert Vessella; Trevor Penning; Rachel Hunter Merrill; Roman Gulati; Bruce Montgomery
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 7.  Future directions in the prevention of prostate cancer.

Authors:  Ian M Thompson; April B Cabang; Michael J Wargovich
Journal:  Nat Rev Clin Oncol       Date:  2013-11-26       Impact factor: 66.675

Review 8.  Concept and viability of androgen annihilation for advanced prostate cancer.

Authors:  James L Mohler
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

Review 9.  [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].

Authors:  L Rinnab; K Gust; R E Hautmann; R Küfer
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

10.  Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice.

Authors:  Tracy Henriques; Xuan Zhang; Frederique B Yiannikouris; Alan Daugherty; Lisa A Cassis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-05-01       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.